Atorvastatin Versus

Dart A, Jerums G, Nicholson G, d Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Braes P, Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997 80(l) 39-44. 

Wienbergen H, Gift AK, Schiele R, et al. MITRA PLUS Study Group. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003 92 285-288. 

Pitt B, Waters D, Brown WV et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators, N Engl J Med 1999 341 70-76. 

As yet there are no completed megatrials with the newer statins. A study that compared atorvastatin versus angioplasty in 341 patients with stable CHD over 18 months was recently reported (Pitt et al., 1999). There were fewer ischemic events in the atorvastatin group, but the difference did not quite reach statistical significance. Furthermore, a previous study had shown a significantly lower incidence of such events in a group treated with conventional medical therapy, because angioplasty can be complicated by myocardial infarction and other acute coronary events (RITA-2 trial participants, 1997). 

SPARCL Atorvastatin versus placebo started within one to six months of... 

Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997 80(1) 39 4. 

Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fiuvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998 81 582-587. 

Atorvastatin, one of the most potent statins available, was used in the Atorvastatin Versus Revascularization Treatments (AVERT) study (29). This study randomized 341 patients with CAD to atorvastatin 80 mg/day vs angioplasty plus usual care. The mean LDL cholesterol in the atorvastatin group was 77 mg/dL compared to 119 mg/dL in the angioplasty group. Therapy with atorvastatin was associated with a significantly longer time to first ischemic event, which corresponded to a risk reduction of 36%. 

Bays HE, Averna M, Majul C, Muller-Wieland D, De PeUegrin A, Giezek H, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary h)percholesterolemia. Am J Cardiol 2013 112 1885-95. 

Cannon CR Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 1495-1 504. 

Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin, versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am.J. Cardiol., 2003, 92, 152-160. 

Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F (2003) Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 15 921-924. Sniderman AD (2004) Is there value in liver function test and creatine phosphokinase monitoring with statin use Am J Cardiol 94 30F-4F. Dujovne CA (2002) Side effects of statins hepatitis versus ransaminitis myositis versus CPKitis . Am J Cardiol 89 1411-1413. 

Athyros VG, Papagrorgious AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Education Program Goal versus... 

Placebo-controlled studies Atorvastatin 10 mg/day has been compared with placebo in 2838 patients with type 2 diabetes melli-tus and no history of coronary heart disease over 3.9 years [41 "]. The percentages of patients with treatment-associated adverse events, serious adverse events, and who withdrew because of adverse events respectively were 23% versus 25%, 1.1% versus 1.1%, and 2.9% versus 3.4%. The most common treatment-associated adverse events were gastrointestinal (8.9% versus 10%) and there was myalgia in (5.0% and 6.0%). 

Cardiovascular As was reported in SEDA-32 (p. 817), ILLUMINATE, an outcome study that recruited around 15 000 statin-eligible patients with coronary heart disease or type 2 diabetes mellitus was terminated after a median follow-up of only 550 days, because of a small but significant increase in major cardiovascular events in those taking torcetrapib - - atorvastatin compared with those taking atorvastatin alone (49 versus 35 cardiovascular deaths) [69. This occurred despite a 72% increase in HDL cholesterol and a 25% reduction in LDL cholesterol compared with the statin alone. This was almost certainly correctly attributed to activation of the renin-angiotensin-aldosterone system, resulting in increments in blood pressure and aldosterone and reduced potassium. 

Wlodarczyk J, Sulhvan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol 2008 102(12) 1654-62. 

Insull Jr. W, Basile JN, Vo AN, Jiang P, Thakkar R, Padley RJ. Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia The SUPREME Study. J Clin Lipidol 2009 3(2) 109-18. 

---